Ten influenza seasons in France: Distribution and timing of influenza A and B circulation, 2003-2013

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Mosnier, Anne ^a,b   Caini, Saverio ^a   Daviaud, Isabelle ^a,b   Bensoussan, Jean Louis ^b   Stoll Keller, Françoise ^c   Bui, Tan Tai ^a   Lina, Bruno ^d   Van der Werf, Sylvie ^e   Cohen, Jean Marie ^a,b  

^a Open Rome (Organize and Promote Epidemiological Network)   (France)

^b Open Rome Coordination Nationale des Groupes Régionaux d'Observation de la Grippe   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d UNIVERSITÉ DE LYON   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

Influenza incidence; Influenza surveillance; Influenza vaccine match; Influenza virus type A; Influenza virus type B; Timing of influenza epidemics

Indexed keywords

ARTICLE; DESCRIPTIVE RESEARCH; DISEASE SURVEILLANCE; EPIDEMIC; FRANCE; HUMAN; INCIDENCE; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEASONAL INFLUENZA; VIRUS STRAIN; VIRUS TYPING; ADULT; FEMALE; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MALE; PRESCHOOL CHILD; PROCEDURES; SEASON; VACCINATION; VIROLOGY;

INFLUENZA VACCINE;

ADULT; CHILD, PRESCHOOL; FEMALE; FRANCE; HUMANS; INCIDENCE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SEASONS; VACCINATION;

EID: 84939536341     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1056-z     Document Type: Article

References (29)

1. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085-94.
2. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-8.
3. World Health Organization. Recommendations on the composition of influenza virus vaccines [http://www.who.int/influenza/vaccines/virus/recommendations/en/]
4. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs. 2012;72(17):2177-85.
5. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10(5):1171-80.
6. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9(6):e98437.
7. Hannoun C, Dab W, Cohen JM. A new influenza surveillance system in France: the Ile-de-France "GROG". 1. Principles and methodology. Eur J Epidemiol. 1989;5(3):285-93.
8. Cohen JM, Mosnier A, Valette M, Bensoussan JL, Van Der Werf S. GROG-I: General practice and surveillance: the example of influenza in France. Med Mal Infect. 2005;35(5):252-6 [Article in French].
9. GROG (Groupes Régionaux d'Observation de la Grippe) [http://www.grog.org/]
10. Biere B, Bauer B, Schweiger B. Differentiation of influenza B virus lineages Yamagata and Victoria by real-time PCR. J Clin Microbiol. 2010;48(4):1425-7.
11. World Health Organization. Information for molecular diagnosis of influenza virus in humans - update August 2011. Available online at: http://www.who.int/influenza/resources/documents/molecular_diagnosis_influenza_virus_humans_update_201108.pdf?ua=1 [Accessed on 9th May 2015].
12. Heikkinen T, Ikonen N, Ziegler T. Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519-24.
13. Paget WJ, Meerhoff TJ, Meijer A, EISS. Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season. Euro Surveill. 2005;10(4):107-11.
14. Meijer A, Paget WJ, Meerhoff TJ, Brown CS, Meuwissen LE, Van der Velden J, et al. Epidemiological and virological assessment of influenza activity in Europe, during the 2004-2005 winter. Euro Surveill. 2006;11(5):111-8.
15. Meijer A, Meerhoff TJ, Meuwissen LE, van der Velden J, Paget WJ, European Influenza Surveillance Scheme. Epidemiological and virological assessment of influenza activity in Europe during the winter 2005-2006. Euro Surveill. 2007;12(9):E11-2.
16. Arkema JM, Meijer A, Meerhoff TJ, Van Der Velden J, Paget WJ, European Influenza Surveillance Scheme (EISS). Epidemiological and virological assessment of influenza activity in Europe, during the 2006-2007 winter. Euro Surveill. 2008;13(34):18958.
17. Snacken R, Broberg E, Beauté J, Lozano JE, Zucs P, Amato-Gauci AJ. Influenza season 2012-2013 in Europe: moderate intensity, mixed (sub)types. Epidemiol Infect. 2014;142(9):1809-12.
18. Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(3):e43-51.
19. Saha S, Chadha M, Al Mamun A, Rahman M, Sturm-Ramirez K, Chittaganpitch M, et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ. 2014;92(5):318-30.
20. Brammer TL, Murray EL, Fukuda K, Hall HE, Klimov A, Cox NJ. Surveillance for influenza--United States, 1997-98, 1998-99, and 1999-00 seasons. MMWR Surveill Summ. 2002;51(7):1-10.
21. Goldstein E, Cobey S, Takahashi S, Miller JC, Lipsitch M. Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. PLoS Med. 2011;8(7):e1001051.
22. van Lier EA, Havelaar AH, Nanda A. The burden of infectious diseases in Europe: a pilot study. Euro Surveill. 2007;12(12):E3-4.
23. Karve S, Meier G, Davis KL, Misurski DA, Wang CC. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013;31(33):3370-88.
24. Silva ML, Perrier L, Späth HM, Grog I, Mosnier A, Havet N, et al. Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health. 2014;14:56.
25. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5):20390.
26. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18(5):20389.
27. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5):20388.
28. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371-6.
29. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59-68.